Endocrinology: What You May Have Missed in 2024
Mohamed Aman,
No information about this author
Athavi Jeevananthan,
No information about this author
Maria Martinez-Cruz
No information about this author
et al.
Annals of Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 31, 2025
During
2024,
there
were
many
practice-changing
innovations
in
the
field
of
endocrinology,
particularly
related
to
use
glucagon-like
peptide-1
receptor
agonists
(GLP-1RAs).
From
substantial
new
evidence
published
10
studies
are
highlighted
that
offer
critical
information
for
clinicians
who
manage
or
comanage
patients
with
endocrine
disorders
including
prediabetes,
diabetes,
obesity,
and
hyperparathyroidism.
Two
articles
focused
on
GLP-1RAs
multiple
clinical
settings
not
studied
original
GLP-1RA
trials,
after
bariatric
surgery
before
endoscopy.
additional
explore
risk
thyroid
cancer
prescribed
effect
a
chronic
kidney
disease
type
2
diabetes.
Three
investigate
opportunities
deintensification
insulin
frequency
an
alternate
method
delivery
One
article
explores
cardiometabolic
effects
intermittent
fasting
persons
prediabetes
The
last
incidence
diabetes
SARS-CoV-2
infection
skeletal
parathyroidectomy
as
treatment
results
each
study
have
direct
care
Language: Английский
Alterations of hepatic lipid content following COVID-19 in persons with type 2 diabetes
Yuliya Kupriyanova,
No information about this author
Iryna Yurchenko,
No information about this author
Pavel Bobrov
No information about this author
et al.
BMJ Open Diabetes Research & Care,
Journal Year:
2025,
Volume and Issue:
13(1), P. e004727 - e004727
Published: Jan. 1, 2025
Introduction
The
study
aimed
to
assess
the
effect
of
COVID-19
on
hepatic
lipid
(HL)
content,
fibrosis
risk,
and
adiposity
in
persons
with
type
2
diabetes.
Research
design
methods
Participants
diabetes
a
history
mild
(n=15,
age
58±12
years,
body
mass
index
30.9±5.2
kg/m
)
were
examined
before
(baseline)
1
year
(12±2
months)
after
(follow-up)
recovery
from
COVID-19.
Investigations
for
changes
metabolic
risk
comprised
clinical
examination,
fasting
blood
sampling
MR-based
measurements.
Potential
corrected
time
course
respective
parameters
group
participants
who
did
not
contract
over
same
(n=14,
61±6
30.0±4.6
).
Results
resulted
relative
increase
HL
content
56%
(95%
CI
18%,
106%;
p=0.04)
measured
as
proton
density
fat
fraction
(HL-PDFF),
absence
While
no
stiffness
volume,
intramyocellular
lipids,
whole-body,
subcutaneous
visceral
adipose
tissue
volumes
well
homeostatic
model
assessment
insulin
resistance
beta-cell
function
observed.
Conclusions
History
is
associated
higher
HL-PDFF
following
infection.
Trial
registration
number
NCT01055093
.
Language: Английский
Long COVID: current research and future directions
Rongling Zhang,
No information about this author
Xiaoying Gu,
No information about this author
Hui Zhang
No information about this author
et al.
Infectious Diseases & Immunity,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 4, 2025
Abstract
Long
coronavirus
disease
(COVID)
is
defined
as
the
continuation
or
development
of
new
symptoms
three
months
after
severe
acute
respiratory
syndrome
2
(SARS-CoV-2)
infection,
and
that
last
for
at
least
two
months,
with
no
other
explanation
their
cause.
This
includes
various
clinical
manifestations
affect
multiple
organ
systems,
such
complications
in
respiratory,
cardiovascular,
neurological,
musculoskeletal
systems.
The
most
commonly
reported
include
fatigue,
cognitive
dysfunction,
dyspnea,
chest
pain;
however,
prevalence
severity
these
vary
greatly
among
individuals.
underlying
mechanisms
long
COVID
are
complex
multifaceted,
encompassing
viral
persistence,
immune
system
mitochondrial
abnormalities,
endothelial
impairment,
alterations
microbiome.
Further,
has
imposed
a
significant
burden
on
individuals,
healthcare
economy
by
impairing
an
individual’s
quality
life
functional
capacity,
thereby
increasing
costs
demand
care
rehabilitation
services.
review
summarizes
definition,
phenotypes,
mechanisms,
current
treatment
advancements
highlights
specific
research
directions
future
investigation.
Language: Английский
Risk of New-Onset Type 2 Diabetes Among Vaccinated Adults After Omicron or Delta Variant SARS-CoV-2 Infection
Liang En Wee,
No information about this author
Jue Tao Lim,
No information about this author
En Yun Loy
No information about this author
et al.
JAMA Network Open,
Journal Year:
2025,
Volume and Issue:
8(4), P. e252959 - e252959
Published: April 2, 2025
This
cohort
study
estimates
the
risk
of
new-onset
type
2
diabetes
after
Delta
or
Omicron
variant
SARS-CoV-2
infection
among
vaccinated
adults
in
Singapore.
Language: Английский
The enduring effect of the COVID-19 pandemic on diabetes
The Lancet Diabetes & Endocrinology,
Journal Year:
2024,
Volume and Issue:
12(8), P. 508 - 510
Published: July 23, 2024
Language: Английский
Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19
Emi E. Nakayama,
No information about this author
Tatsuo Shioda
No information about this author
Pathogens,
Journal Year:
2024,
Volume and Issue:
13(12), P. 1109 - 1109
Published: Dec. 15, 2024
Antibody-dependent
enhancement
(ADE)
is
a
phenomenon
in
which
antibodies
enhance
subsequent
viral
infections
rather
than
preventing
them.
Sub-optimal
levels
of
neutralizing
individuals
infected
with
dengue
virus
are
known
to
be
associated
severe
disease
upon
reinfection
different
serotype.
For
Severe
Acute
Respiratory
Syndrome
Coronavirus
type-2
infection,
three
types
ADE
have
been
proposed:
(1)
Fc
receptor-dependent
infection
cells
expressing
receptors,
such
as
macrophages
by
anti-spike
antibodies,
(2)
receptor-independent
epithelial
and
(3)
cytokine
production
anti-nucleocapsid
antibodies.
This
review
focuses
on
the
induced
examining
its
potential
role
COVID-19
during
contribution
post-acute
sequelae
COVID-19,
i.e.,
prolonged
symptoms
lasting
at
least
months
after
acute
phase
disease.
We
also
discuss
protective
effects
recently
identified
that
neutralize
Omicron
variants.
Language: Английский
Incidence of diabetes mellitus following hospitalisation for COVID‐19 in the United Kingdom: A prospective observational study
Diabetes Obesity and Metabolism,
Journal Year:
2024,
Volume and Issue:
27(2), P. 767 - 776
Published: Nov. 20, 2024
Abstract
Background
People
hospitalised
for
coronavirus
disease
2019
(COVID‐19)
have
elevated
incidence
of
diabetes.
However,
it
is
unclear
whether
this
due
to
shared
risk
factors,
confounding
or
stress
hyperglycaemia
in
response
acute
illness.
Methods
We
analysed
a
multicentre
prospective
cohort
study
(PHOSP‐COVID)
people
≥18
years
discharged
from
NHS
hospitals
across
the
United
Kingdom
following
COVID‐19.
Individuals
were
included
if
they
attended
at
least
one
research
visit
with
HbA1c
measurement
within
14
months
discharge
and
had
no
history
diabetes
baseline.
The
primary
outcome
was
new
onset
(any
type),
as
defined
by
first
glycated
haemoglobin
(HbA1c)
≥6.5%
(≥48
mmol/mol).
Follow‐up
censored
last
measurement.
Age‐standardised
rates
rate
ratios
(adjusted
age,
sex,
ethnicity,
length
hospital
stay,
body
mass
index,
smoking,
physical
activity,
deprivation,
hypertension,
hyperlipidaemia/hypercholesterolaemia,
intensive
therapy
unit
admission,
invasive
mechanical
ventilation,
corticosteroid
use
C‐reactive
protein
score)
calculated
using
Poisson
regression.
Incidence
compared
control
groups
published
clinical
trials
applying
same
inclusion
exclusion
criteria,
where
possible.
Results
91.4
per
1000
person‐years
higher
South
Asian
(incidence
[IRR]
=
3.60;
1.77,
7.32;
p
<
0.001)
Black
ethnic
(IRR
2.36;
1.07,
5.21;
0.03)
White
groups.
When
restricted
similar
characteristics,
those
UK
data.
Conclusion
Diabetes
hospitalisation
COVID‐19
high,
but
remains
uncertain
disproportionately
than
pre‐pandemic
levels.
Language: Английский
Immunological characteristics in elderly COVID-19 patients: a post-COVID era analysis
Yunhui Li,
No information about this author
Yuan Chen,
No information about this author
Jing Liang
No information about this author
et al.
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2024,
Volume and Issue:
14
Published: Nov. 29, 2024
Advanced
age
is
a
primary
risk
factor
for
adverse
COVID-19
outcomes,
potentially
attributed
to
immunosenescence
and
dysregulated
inflammatory
responses.
In
the
post-pandemic
era,
with
containment
measures
lifted,
elderly
remain
particularly
susceptible,
highlighting
need
intensified
focus
on
immune
health
management.
Language: Английский